1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Cellectis soars as Pfizer fronts $80m for immuno-oncology

 
• By Sukaina Virji

Pfizer is paying $80m up front to French company Cellectis for access to its CAR-T platform, an allogeneic cell therapy approach to treating cancer with the aim of developing 'off-the-shelf' immunotherapies. Cellectis's Chimeric Antigen Receptor T-cell (CAR-T) technology uses engineered T-cells from a single donor for use in multiple patients, compared with autologous approaches which require engineering of a patient's own T-cells to target tumor cells.

Pfizer is paying $80m up front to French company Cellectis for access to its CAR-T platform, an allogeneic cell therapy approach to treating cancer with the aim of developing 'off-the-shelf' immunotherapies. Cellectis's Chimeric Antigen Receptor T-cell (CAR-T) technology uses engineered T-cells from a single donor for use in multiple patients, compared with autologous approaches which require engineering of a patient's own T-cells to target tumor cells.

Pfizer of course just missed out on buying in major immuno-oncology expertise when AstraZeneca (with its MedImmune subsidiary) turned down...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 
• By Andrew McConaghie

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.